Ruxolitinib and Steroid as First Line Therapy for Acute GVHD
Status:
Unknown status
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of ruxolitinib in combination with
methylprednisolone as first line therapy in patients with Grades II to IV acute
graft-versus-host disease (GVHD).
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine